Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics appoints Michael Khan as chief medical adviser

Will advise on translational research for its siRNA-based therapeutics

UK-based biotech Silence Therapeutics has appointed Dr Michael Khan as the company's chief medical adviser.

Dr Khan is an associate professor of medicine at the University of Warwick and a consultant physician at University Hospitals.

In his role as adviser, he will help Silence develop translational clinical research involving its siRNA-based therapeutics for the treatment of orphan diseases, and those conditions with current unmet medical need.

“I believe that Silence Therapeutics core technologies are uniquely positioned to fulfil these needs,” said Dr Khan.

Dr Khan's previous roles include head of molecular medicine at Warwick University, where he helped develop various projects in cell and molecular biology.

His work has covered cancer and diabetes, and he has written several books on the subjects. He also teaches postgraduates and undergraduates in medicine and biological sciences in these areas.

In addition, Dr Khan is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK.

“Michael's medical, clinical and regulatory experience will be invaluable as we look to commercialise our prospects,” said Klaus Giese, chief scientific officer of Silence.

20th September 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment
Exploring the evolution of patient involvement in health technology assessment (HTA), and the role of the patient voice in market access....

Infographics